Last reviewed · How we verify
Fluticasone propionate 500 mcg
Fluticasone propionate 500 mcg is a Small molecule drug developed by Novartis Pharmaceuticals. It is currently FDA-approved.
At a glance
| Generic name | Fluticasone propionate 500 mcg |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers (PHASE4)
- Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) (PHASE3)
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (PHASE1)
- Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (PHASE4)
- Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older (PHASE1)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone propionate 500 mcg CI brief — competitive landscape report
- Fluticasone propionate 500 mcg updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI
Frequently asked questions about Fluticasone propionate 500 mcg
What is Fluticasone propionate 500 mcg?
Fluticasone propionate 500 mcg is a Small molecule drug developed by Novartis Pharmaceuticals.
Who makes Fluticasone propionate 500 mcg?
Fluticasone propionate 500 mcg is developed and marketed by Novartis Pharmaceuticals (see full Novartis Pharmaceuticals pipeline at /company/novartis-pharmaceuticals).
What development phase is Fluticasone propionate 500 mcg in?
Fluticasone propionate 500 mcg is FDA-approved (marketed).